News

September 2021 Following an update to the Dexcom account creation interface from 9th of September 2021, selected new Dexcom G5 Mobile customers may need to complete an additional step when creating their Dexcom account. This update will not affect existing Dexcom G5 Mobile customers. For further information, please refer to this document. The update introduces …

Continue reading "Update Prompts Additional Step in Setting up Dexcom Account for some New Customers"

August 2021 Richard Plowright, Managing Director and Owner of Australasian Medical & Scientific Limited (AMSL) and New Zealand Medical & Scientific (NZMS) has announced his retirement, after over 30 years of providing the Australasian market with access to leading edge healthcare solutions from all over the world. As of the 1st August 2021, Richard has …

Continue reading "Dexcom, Inc. acquires AMSL and NZMS"

7th April 2021 The Therapeutic Goods Administration (TGA) suspension of the ARTG entry for the Tandem Diabetes Care t:slim X2 insulin pump has officially been lifted. AMSL Diabetes and Tandem Diabetes Care have been in discussions with the TGA and have now successfully addressed their concerns for the t:slim X2 insulin pump. For more information …

Continue reading "Tandem t:slim X2 Insulin Pump Suspension Lifted"

29th March 2021 As of 29th March 2021, AMSL Diabetes has discontinued the sale of the t:slim X2 insulin pump with Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) integration. This announcement does not affect the supply of the t:slim X2 insulin pump with Basal-IQ™ technology and any subsequent versions of the pump. Existing customers will …

Continue reading "Tandem t:slim X2 Insulin Pump with Dexcom G5 Mobile Integration Supply Update"

15th January 2021 The Australian Government has updated the NDSS CGM Subsidy Initiative to include the NEW Dexcom G6 Continuous Glucose Monitoring System. As of Monday 18th of January 2021,  if you are using a Tandem t:slim X2 insulin pump and are eligible for the NDSS CGM Subsidy Initiative you can now have access to …

Continue reading "The Australian Government has updated the NDSS CGM Subsidy Initiative"

24th November 2020 Recently the Therapeutic Goods Administration (TGA) expressed concern about the Tandem Diabetes Care t:slim X2 insulin pump. AMSL Diabetes and Tandem Diabetes Care have been in discussions with the TGA to address their concern. However the TGA have informed us of their intent to temporarily suspend the ARTG entry for the t:slim …

Continue reading "Tandem Suspension Notice (Last Updated 1 April 2021)"

Dexcom G4 PLATINUM manufactured by Dexcom has been discontinued for sales directly from AMSL Diabetes.

Basal-IQ technology is now available in Australia!  The t:slim X2 insulin pump with Basal-IQ technology is compatible with the new Dexcom G6 CGM System.

On the 2nd April 2020, Dexcom announced the upcoming obsolescence for Dexcom G4 PLATINUM and Dexcom G5 Mobile at dexcom.com/obsolescence. This specific announcement and timeline is only applicable to residents of the United States.

Important Message from AMSL General Manager, Ian Slater on COVID-19 23rd March 2020 The impact of COVID-19 has been unprecedented as it continues to affect people and organisations around the world. The Federal Government, State Governments and Health Authorities continue to provide detailed guidelines on how to mitigate risks and ensure containment. We encourage all …

Continue reading "Important Update: AMSL’s Commitment during COVID-19"

Sydney, Australia, March 2020 The Dexcom G6 Continuous Glucose Monitoring (CGM) System, has been registered in Australia (ARTG 330535).                                                                 Dexcom G6 represents the latest …

Continue reading "Dexcom G6 CGM System Update"

Sydney, Australia, March 2020 The Australian Government is simplifying the clinical eligibility criteria for the Continuous Glucose Monitoring (CGM) Initiative from the 1st of March, 2020. This will allow people with type 1 diabetes under the age of 21, and those over the age of 21 who have valid concessional status to access fully subsidised CGM …

Continue reading "The Australian Government Simplifies the Clinical Eligibility Criteria for the Continuous Glucose Monitoring (CGM) Initiative"

Sydney, Australia, May 2019 AMSL Diabetes are excited to announce that they have signed a distribution agreement with MannKind Corporation (NASDAQ: MNKD) to introduce their patient-focused therapies to the Australian market. The exclusive partnership is set to benefit Australian diabetes patients by offering a new innovative technology solution for their diabetes management. “We are excited …

Continue reading "AMSL Diabetes Partner with MannKind Corporation"

Sydney, Australia, April 2019 AMSL Diabetes are delighted to announce that they have agreed to distribute MedAngel products in Australia.                                                                        …

Continue reading "AMSL Diabetes to distribute MedAngel ONE in Australia"

Sydney, Australia, November 2018 Inclusion of LifeScan OneTouch Blood Glucose Test Strips on the NDSS Product Schedule.                                                                   The Australian Government recently undertook a …

Continue reading "NDSS Blood Glucose Strips Review Press Release"

Sydney, Australia, August 2018 AMSL Diabetes are delighted to announce they have partnered with Tandem Diabetes Care®, Inc. AMSL Diabetes have partnered with Tandem Diabetes Care, to introduce their innovative product range to the Australian market for the very first time. The exclusive partnership is set to benefit Australian type 1 diabetes patients by offering …

Continue reading "Tandem Diabetes Care Partnership Announcement"